8-K current report · filed Nov 5, 2026

Inogen Inc (INGN) 8-K Current Report: November 5, 2026

Item 2.01Item 2.02Item 5.02Item 7.01Item 8.01Item EX-99.1Item EX-99.2INGN overview

Short answer

Inogen Inc (INGN) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Completed sale of U.S. oxygen rental business to Rotech on November 2, 2026.

Inogen Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Completed sale of U.S. oxygen rental business to Rotech on November 2, 2026
  • Assets transferred: specified on-rent and on-hand inventory plus related patient records
  • Purchase price up to approximately $24.8 million, subject to post-closing reconciliation
  • Six-installment payment structure, creating future cash receipts rather than immediate full proceeds
  • Transaction exits Inogen’s U.S. rental operations, shifting focus away from that business segment

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026, announced November 5, 2026
  • Press release includes update on completed sale of Inogen’s U.S. rental business
  • Investors should review Exhibit 99.2 for financial figures and transaction details

Item 5.02 · Departure/Election of Directors or Officers

  • Andy Reding appointed President, CEO and Class III director through 2029, replacing Kevin Smith effective October 30, 2026
  • No COO successor planned, concentrating operating responsibilities under the new CEO
  • Compensation: $700,000 salary, 100% target bonus, $300,000 signing bonus
  • Equity package: 337,500 shares, split equally between time-based RSUs and performance-based PSUs, targeted for 2027 grants
  • Severance exposure: 24 months’ salary, plus target bonus during the change-of-control period; Smith separation terms remain pending disclosure

Item 7.01 · Regulation FD Disclosure

  • Press release announces completion of Inogen’s previously disclosed U.S. rental business sale
  • Transaction marks exit from the U.S. rental business, affecting revenue mix and operating strategy
  • Investors should review the Item 2.02 press release for transaction proceeds and financial impact

Item 8.01 · Other Events

  • Board proposing annual director elections, replacing the classified board structure at the 2027 annual meeting
  • Charter declassification previously won over 99% of votes cast, but failed the 66 2/3% outstanding-share threshold
  • Supermajority voting requirements targeted for elimination, potentially lowering approval barriers for future governance changes
  • Cost reduction program follows U.S. rental-business divestiture, targeting approximately $20 million in annualized savings
  • Approximately half of savings expected in fourth-quarter 2026, with remainder realized throughout 2027; restructuring charges remain unestimated

Item EX-99.1 · Exhibit EX-99.1

  • COO Andy Reding appointed President, CEO, and director, succeeding Kevin Smith
  • Leadership change signals Board push to improve execution and restore sustainable, profitable growth
  • Reding brings respiratory-care and medical-device commercialization experience from Viant Medical and Hillrom Respiratory Health
  • Reding led a central role in the Rotech divestiture, supporting Inogen’s shift toward a streamlined commercial model
  • Third-quarter 2026 results, for the period ended September 30, scheduled separately with a 5:00 p.m. ET investor call

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $77.2M, down 2.4% YoY, with U.S. growth 3.8% offset by international sales weakness
  • Adjusted loss $0.4M versus $1.2M earnings, while GAAP loss widened to $14.8M, including a $10.6M impairment charge
  • Rental divestiture completed for up to $24.8M, simplifying operations but shifting results to continuing operations
  • $20M annualized cost reduction program targeted by end-2027, supporting profitability but requiring execution
  • Cash and securities $97.7M, no debt, with share repurchase authorization increased $15M to $45M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Inogen Inc 8-K filings

Get the next INGN 8-K as it lands

Follow INGN for push alerts, or ask the research agent what this filing means.